CD274 and endometrial carcinoma: Since the approval of pembrolizumab in 2014 for the treatment of advanced melanoma, PD-1/PD-L1 ICIs have revolutionized treatment modes ranging from Hodgkin lymphoma to advanced endometrial carcinoma [30].